Given the marked enrichment of Faecalimonas observed in our UFPF IBD cohort, which was comprised of patients in remission, this association holds particular relevance for IBD patients, as the use of anti-TNF therapies may possibly induce positive shifts in gut microbiome composition that could potentially be protective against the development of future inflammation-associated diseases like PD. Here, TNF is linked to Parkinson disease.